单次注射钆基对比剂后脑蛋白成分中钆的尺寸排阻色谱定量分析
研究将30只ddY小鼠随机分为三组,分别静脉注射线性钆基对比剂钆双胺、大环类钆布醇或钆特酸(5 mmol/kg),对照组5只注射生理盐水,于注射后5分钟和10天取脑脊液、脉络丛、脑膜及血管、各脑区,用尺寸排阻色谱分离蛋白后以电感耦合等离子体质谱定量钆。结果显示钆基对比剂可能穿过完整脑屏障,化学结构影响钆入脑能力,钆双胺和钆布醇滞留的钆可能与蛋白等有机分子结合。
要点
- 注射后5分钟,钆双胺组脑各部位钆浓度最高,钆特酸组最低(p < .05)。
- 注射后10天,所有钆基对比剂的钆均显著下降(p < 0.01),钆双胺的钆以多种大小分子分布于全脑。
- 钆布醇组嗅球钆浓度(8.7 ± 4.5 nmol)显著高于脑其他部位。
核心结论
- 钆基对比剂可能穿过完整脑屏障,其化学结构可能影响钆的入脑能力;钆双胺和钆布醇在脑组织滞留的钆可能与包括蛋白在内的有机分子结合。
研究设计与样本
- 动物实验:30只ddY小鼠随机分为三组,分别静脉注射钆双胺(线性)、钆布醇(大环类)或钆特酸(大环类),剂量5 mmol/kg,对照组5只注射250 µL生理盐水;注射后5分钟和10天采集脑脊液、脉络丛、脑膜及血管,并取嗅球、大脑皮质、海马、小脑和脑干,蛋白经尺寸排阻高效液相色谱分离,钆浓度用电感耦合等离子体质谱定量。
关键影像表现/征象
- 注射后5分钟,钆双胺组脑脊液钆浓度最高(578.4 ± 135.3 nmol),钆布醇组脑膜及血管钆浓度最高(379.7 ± 75.4 nmol)。
- 注射后10天,钆双胺的钆以多种不同大小分子分布于全脑,钆布醇的钆在嗅球(8.7 ± 4.5 nmol)显著高于脑其他部位。
- 钆布醇的钆大部分存在于与钆布醇大小相似的分子中,但也见于分子尺寸大于对比剂的多种蛋白分子。
- 钆特酸的钆仅少量存在于脑中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the role of transporter proteins in gadolinium (Gd) distribution and retention in the brain after one high-dose injection of Gd-based contrast agent (GBCA).
METHODS AND MATERIALS: 30 ddY mice were randomly divided into three treatment groups to be intravenously injected with either Gadodiamide (linear GBCA), Gadobutrol (macrocyclic GBCA), or Gadoterate (macrocyclic GBCA) at a dose of 5 mmol/kg, while five mice in the control group received 250 µL saline. Five minutes (5 min) and ten days (10d) post-injection, the cerebrospinal fluid (CSF), choroid plexus (CP), and meninges and associated vasculature (MAV) were collected. The brain was then dissected to obtain the olfactory bulb, cerebral cortex, hippocampus, cerebellum, and brainstem. Proteins were extracted and separated by a size-exclusion high-performance liquid chromatography (SEC) system, and Gd concentrations were quantified by inductively coupled plasma mass spectrometry (ICP-MS).
RESULTS: 5 m post-injection, the Gadodiamide group had the highest Gd concentration, while Gadoterate had the lowest Gd concentration in all parts of the brain (p < .05). Gd concentration was highest in the cerebrospinal fluid (CSF) of the Gadodiamide group (578.4 ± 135.3 nmol), while Gd concentration was highest in MAV in the Gadobutrol group (379.7 ± 75.4 nmol) at 5 min post-injection. At 10d, in spite of the significant decrease of Gd from all GBCAs ( p < 0.01), retained Gd from Gadodiamide was detected all over the brain in several molecules that varied in size. Gd from Gadobutrol detected in the olfactory bulb (8.7 ± 4.5 nmol) was significantly higher than in other parts of the brain. Although most Gd from Gadobutrol was found in molecules similar in size to Gadobutrol, it was also found in several protein molecules of molecular size larger than the contrast agents. Only a small amount of Gd from Gadoterate was found in the brain.
CONCLUSION: GBCAs may be able to pass through intact brain barriers, and the chemical structures of GBCAs may affect the penetration capability of Gd into the brain. Retained Gd in the brain tissue from Gadodiamide and Gadobutrol may be bound to some organic molecules, including proteins.
ADVANCES IN KNOWLEDGE: Intact GBCA are able to penetrate a series of brain barrier immediately after administration regardless the type of the chelate. Gd may be bound with macromolecules that may cause Gd retention in the brain.
引用
- Kartamihardja AAP, Hanaoka H, Andriana P, et al. Quantitative analysis of Gd in the protein content of the brain following single injection of gadolinium-based contrast agents (GBCAs) by size exclusion chromatography. Br J Radiol. 2019. PMID: 31045442. doi:10.1259/bjr.20190062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。